Letter to the Editor Regarding “Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma”

IF 4.3 Q1 Medicine

Biology of Blood and Marrow Transplantation Pub Date : 2020-12-01 DOI:10.1016/j.bbmt.2020.08.032

Jie Zhang , Junlong Li , Qiufei Ma , Hongbo Yang , James Signorovitch , Eric Wu

引用次数: 2

查看原文本刊更多论文

致编辑的关于“比较阿西卡他格西洛鲁与Tisagenlecleucel治疗复发/难治性大B细胞淋巴瘤的疗效、安全性和预输注时间”的信

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biology of Blood and Marrow Transplantation 医学-免疫学

CiteScore

6.60

自引率

0.00%

发文量

1061

审稿时长

3-6 weeks

期刊介绍： Biology of Blood and Marrow Transplantation publishes original research reports, reviews, editorials, commentaries, letters to the editor, and hypotheses and is the official publication of the American Society for Transplantation and Cellular Therapy. The journal focuses on current technology and knowledge in the interdisciplinary field of hematopoetic stem cell transplantation.